ACELRX PHARMACEUT. DL-01 Cash Flow Conversion Efficiency
ACELRX PHARMACEUT. DL-01 cash flow conversion efficiency. Based on the latest financial reports, ACELRX PHARMACEUT. DL-01 (R5XA) has a cash flow conversion efficiency ratio of -0.143x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.44 Million ≈ $-2.85 Million USD) by net assets (€17.04 Million ≈ $19.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ACELRX PHARMACEUT. DL-01 (2021–2025)
Cash flow conversion efficiency of ACELRX PHARMACEUT. DL-01 from 2021 to 2025. This chart illustrates how ACELRX PHARMACEUT. DL-01's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ACELRX PHARMACEUT. DL-01 (R5XA) share price today for real-time trading data and today's change.
ACELRX PHARMACEUT. DL-01 Cash Flow Conversion Ratio Explained
ACELRX PHARMACEUT. DL-01 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ACELRX PHARMACEUT. DL-01 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACELRX PHARMACEUT. DL-01 ranked by their cash flow conversion efficiency. Also see R5XA company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HLV LIMITED
NSE:HLVLTD
|
0.007x |
|
Eightco Holdings Inc.
NASDAQ:OCTO
|
-0.078x |
|
Corline Biomedical AB
ST:CLBIO
|
0.001x |
|
Dividend Select 15 Corp
TO:DS
|
0.006x |
|
Suratwwala Business Group Limited
NSE:SBGLP
|
0.004x |
|
Rubicon Water Ltd
AU:RWL
|
0.155x |
|
KRONA PUBLIC REAL ESTATE
F:927
|
-0.037x |
|
Indopoly Swakarsa Industry Tbk
JK:IPOL
|
0.051x |
Annual Cash Flow Conversion Efficiency for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ACELRX PHARMACEUT. DL-01 from 2021 to 2025. Review R5XA free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €17.04 Million ≈ $19.92 Million |
€-11.36 Million ≈ $-13.29 Million |
-0.667x | +57.92% |
| 2024-12-31 | €8.00 Million ≈ $9.35 Million |
€-12.68 Million ≈ $-14.83 Million |
-1.585x | -27.82% |
| 2023-12-31 | €14.11 Million ≈ $16.49 Million |
€-17.49 Million ≈ $-20.45 Million |
-1.240x | +4.51% |
| 2022-12-31 | €21.81 Million ≈ $25.50 Million |
€-28.33 Million ≈ $-33.12 Million |
-1.299x | -255.38% |
| 2021-12-31 | €-35.89 Million ≈ $-41.96 Million |
€-30.00 Million ≈ $-35.08 Million |
0.836x | -- |
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more